Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e010064
DOI: 10.1136/jitc-2024-010064 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.11.2024. Verfasst von Xiaojie Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key R&D Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Background
CAR-T-cell therapy and bispecific antibody have revolutionized the treatment landscape for multiple myeloma. However, there is currently a lack of studies comparing the efficacy and safety of these two approaches. This meta-analysis assesses the efficacy and safety of B-cell maturation antigen (BCMA)-directed CAR-T-cell therapies and BCMA×CD3 bispecific antibodies as third-line or later interventions for relapsed/refractory multiple myeloma (RRMM).
Methods
We searched PubMed, Embase, Web of Science, and Cochrane databases up to May 31, 2024, identifying 11 eligible studies encompassing 1269 participants. Random-effects models evaluated the primary (complete response (CR) rate) and secondary (overall response rate (ORR)) outcomes, while meta-regression analyses adjusted for relevant covariates.
Results
CAR-T-cell therapy achieved significantly higher pooled CR rate (0.54 (95% CI 0.42–0.69) vs bispecific antibodies 0.35 (0.30–0.41), p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Capital Medical University, Beijing, China.
- Peking University Sixth Hospital, Beijing, China.
- Department of Hematology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.
- Department of Radiology, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China.
- Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China wangliangtrhos@126.com.
ORCID-Profile: Xiaojie Liang, Yufan Wang, Baiwei Luo, Bingyu Lin, WeiXiang Lu, Shengyu Tian, Dan Liu, Liang Wang
Förderung
- Key R&D Program of China
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
- Beijing Physician Scientist Training Project
Zitieren
APA
Liang, X., Wang, Y., Luo, B., Lin, B., Lu, W., Tian, S., Liu, D., & Wang, L. (2024). Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. Journal for ImmunoTherapy of Cancer, 12(11), e010064. https://doi.org/10.1136/jitc-2024-010064
Vancouver
Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S, et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. Journal for ImmunoTherapy of Cancer. 2024;12(11):e010064. doi:10.1136/jitc-2024-010064
BibTeX
@article{Liang2024,
author = {Liang, Xiaojie and Wang, Yufan and Luo, Baiwei and Lin, Bingyu and Lu, WeiXiang and Tian, Shengyu and Liu, Dan and Wang, Liang},
title = {Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {11},
pages = {e010064},
doi = {10.1136/jitc-2024-010064}
}
EUVIMED